Yasuhiro Hagiwara

Learn More
OBJECTIVE To investigate the status of education and employment of long-term survivors who became physically handicapped after treatment for high-grade osteosarcoma. METHODS Of the osteosarcoma patients treated at our hospital, 41 patients aged less than 18 years at the initial presentation who were free of disease for 10 years or longer after the end of(More)
Non-inferiority for overall survival (OS) following alternate-day treatment with the oral anticancer drug S-1 compared with standard daily treatment was assessed in Japanese patients with unresectable advanced pancreatic cancer in a multicenter, randomized, phase II study. This trial was registered at the UMIN Clinical Trials Registry (no. 000008604).(More)
This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment. This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cost-effectiveness was a secondary endpoint of the SELECT BC trial, some of the randomized(More)
Trialists and epidemiologists often employ different terminology to refer to biases in randomized trials and observational studies, even though many biases have a similar structure in both types of study. We use causal diagrams to represent the structure of biases, as described by Cochrane for randomized trials, and provide a translation to the usual(More)
The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial. In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or(More)
OBJECTIVE This study was performed to compare health-related quality of life (HRQOL) of gemcitabine plus S-1 (GS), S-1 alone and gemcitabine alone as first-line chemotherapy for locally advanced or metastatic pancreatic cancer in the GEST (Gemcitabine and TS-1 Trial) study and to assess the impacts of adverse events and tumour response on HRQOL. METHODS(More)
OBJECTIVE To evaluate the effects of S-1, an orally administered 5-FU agent, versus taxane on patient-reported outcomes (PROs) in the SELECT BC trial. METHODS Patients with HER2-negative and endocrine treatment-resistant breast cancer with metastasis or recurrence after surgery were randomly assigned to receive first-line taxane or S-1. PROs (secondary(More)
Title: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial Authors: Takeru Shiroiwa (t.shiroiwa@gmail.com) Takashi Fukuda (t-fukuda@niph.go.jp) Kojiro Shimozuma (k.shimozuma@gmail.com) Mitsuko Mouri (gh-mouri@newkast.or.jp) Yasuhiro(More)
OBJECTIVE We assessed the impact of treatment preferences in second-line chemotherapy on breast cancer prognosis using the SELECT BC study. METHODS The SELECT BC study was performed in patients with HER2-negative metastatic breast cancer treated with initial chemotherapy. From these patients, 618 were assigned to 2 groups (S-1 group, 309; taxane group,(More)